Search results for "relation"

showing 10 items of 10542 documents

Effect of β-cryptoxanthin plus phytosterols on cardiovascular risk and bone turnover markers in post-menopausal women: a randomized crossover trial.

2014

Abstract Background and aim Post-menopausal women are at higher risk of cardiovascular disease and bone demineralization. Phytosterols (PS) may be used for hypercholesterolemia in some groups and β-cryptoxanthin (β-Cx) displays a unique anabolic effect on bone. Our aim was to assess the changes in cardiovascular and bone turnover markers from the oral intake of β-Cx and PS in post-menopausal women. Methods and results A randomized, double-blind, crossover study with β-Cx (0.75 mg/day) and PS (1.5 g/day), single and combined, was performed in 38 postmenopausal women. Diet was supplemented with 1 × 250 mL milk-based fruit drink/day for 4 weeks with a wash-out period of 4-weeks in between. Ser…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismCampesterolOsteoporosisHypercholesterolemiaMedicine (miscellaneous)Parathyroid hormoneAdministration OralGastroenterologyBone and BonesBone remodelingchemistry.chemical_compoundDouble-Blind MethodRisk FactorsInternal medicineStatistical significancemedicineHumansCryptoxanthinsTriglyceridesAgedNutrition and DieteticsCross-Over StudiesDose-Response Relationship Drugbusiness.industryCholesterol HDLPhytosterolsCholesterol LDLMiddle Agedmedicine.diseaseCrossover studySitosterolsHealthy VolunteersClinical trialPostmenopauseEndocrinologyCholesterolTreatment OutcomechemistrySelective estrogen receptor modulatorCardiovascular DiseasesDietary SupplementsFemaleCardiology and Cardiovascular MedicinebusinessNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women

2006

To investigate the effects of a low transdermal estradiol dose on bone metabolism and to compare it with both the standard dose and absence of treatment.In this study performed in a third-level academic center, 66 healthy postmenopausal women underwent hormone therapy (HT) with patches containing estradiol at standard (0.050 mg/day, HT50, 33 women) or low dosage (0.025 mg/day, HT25, 33 women) and 70 women were without treatment (NT). The values (mean of three samples) of several bone biochemical parameters were compared between groups after adjusting for confounding factors. Bone mineral density (BMD) was assessed (by dual-energy X-ray absorptiometry) in the spine and hip in all cases, and …

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisCollagen Type IBone remodelingEndocrinologyBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalTransdermalBone mineralAnalysis of VarianceDose-Response Relationship DrugEstradiolbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle AgedAlkaline Phosphatasemedicine.diseasePostmenopauseMenopauseDose–response relationshipEndocrinologyFemaleHormone therapyPeptidesDensitometrybusinessBiomarkersGynecological Endocrinology
researchProduct

Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2

2005

Objective To examine the effects of raloxifene on prostacyclin production by human umbilical vein endothelial cells (HUVEC) and to shed light on the molecular details of that action. Design Cell culture for 4, 8, 16, 24, and 48 hours. Setting University research laboratory. Patient(s) Source of HUVEC. Intervention(s) Measurement of prostacyclin production and of protein levels and mRNA expression of cyclooxygenase (COX)-1 and -2. Main Outcome Measure(s) Prostacyclin production was measured by enzyme immunoassay, the mRNA expression of COX-1 was measured by quantitative real time-polymerase chain reaction, and the protein levels of COX-1 and -2 were measured by immunoblotting. Result(s) Ralo…

medicine.medical_specialtyEndotheliumAgonist-antagonistEstrogen receptorProstacyclinPharmacologyGene Expression Regulation EnzymologicUmbilical veinInternal medicinemedicineHumansCyclooxygenase InhibitorsRaloxifeneCells CulturedDose-Response Relationship DrugbiologyChemistryEndothelial CellsObstetrics and GynecologyEpoprostenolEndothelial stem cellmedicine.anatomical_structureEndocrinologyReproductive MedicineCyclooxygenase 2Raloxifene HydrochlorideCyclooxygenase 1biology.proteinCyclooxygenasemedicine.drugFertility and Sterility
researchProduct

Characteristics of histamine tachyphylaxis in rat uterine smooth muscle.

2002

Objective and design: To study both the desensitisation induced by short-term exposure to histamine and the mechanism responsible in the isolated rat uterus.¶Material: Precontracted isolated uterus (37 mM KCl) from oestrogenised Wistar rats were used.¶Treatment: Repetitive responses to histamine (10–6, 10–5, 10–4, 10–3 M), dimaprit and clonidine (10–4 M) were tested at 15, 30, 45 and 105 min., with their modifications by (5 mg/ kg, 24 h before sacrifice) reserpine, 10–7 M propranolol, 10–8 M atropine, and 10–6 M indomethacin. Dose-response curves for adrenaline were carried out as standard protocol.¶Methods: In vitro techniques (de Jalon's solution, 31°C, carbogen, isotonic registration, re…

medicine.medical_specialtyEpinephrineMuscle RelaxationImmunologyPropranololTachyphylaxisIn Vitro TechniquesClonidineHistamine Agonistschemistry.chemical_compoundUterine ContractionDimapritInternal medicinemedicineCyclic AMPAnimalsIsotonic ContractionRats WistarTachyphylaxisPharmacologyDose-Response Relationship Drugbusiness.industryUterusEstrogensReserpineDimapritClonidineRatsAtropineDose–response relationshipEndocrinologychemistryFemalebusinessAdrenergic alpha-AgonistsHistaminemedicine.drugHistamineInflammation research : official journal of the European Histamine Research Society ... [et al.]
researchProduct

Personalised Medicine in National Cancer Plans: How Can Innovation Be Translated Into Policy?

2014

ABSTRACT Stratified, precision or personalised medicine (PM) is emerging as one of the most important areas of clinical innovation in cancer care. Yet, implementing policies to translate these innovations to practice entails deep changes, including in how patient information is treated, how funding is allocated, how diagnostic tests are validated and carried out, how care is organised, how clinical trials are conducted and how new drugs are approved. National Cancer Control Programmes (NCCPs), for their part, have emerged as the primary instrument to coordinate the range of cancer control policies within individual countries, and virtually all European countries have adopted one. This means…

medicine.medical_specialtyEvidence-based practicebusiness.industryProfessional developmentConflict of interestHealth services researchHematologyPublic relationsBest interestsBiobankOncologyFamily medicineHealth caremedicinebusinessPatient educationAnnals of Oncology
researchProduct

Inhibition of intracellular Ca2+ release by a Rho-kinase inhibitor for the treatment of ischemic damage in primary cultured rat hippocampal neurons.

2008

The effects of hydroxy fasudil, a specific Rho-kinase inhibitor, on behavior and brain neuronal activity in animal studies have been described previously. However, whether a Rho-kinase inhibitor can directly protect neurons against ischemic damage and the molecular mechanisms underlying these effects are poorly understood. The present work was designed to investigate the effect of hydroxy fasudil against oxygen-glucose deprivation (OGD) induced acute neuronal injury and the underlying mechanisms in vitro. Pretreatment with hydroxy fasudil at 5 and 10 microM could concentration-dependently improve cell viability and decrease Lactate dehydrogenase (LDH) level in extracellular solution of neur…

medicine.medical_specialtyExcitotoxicityIntracellular SpaceGlutamic AcidBiologymedicine.disease_causeNeuroprotectionHippocampusCalcium in biologyPotassium ChlorideRats Sprague-DawleyCalcium imagingAdenosine TriphosphateIschemiaInternal medicine1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinemedicineAnimalsHypoxiaProtein Kinase InhibitorsCells CulturedPharmacologyNeuronsrho-Associated KinasesDose-Response Relationship DrugCalcium channelFasudilGlutamate receptorRatsEndocrinologyGlucoseRho kinase inhibitorCalciumEuropean journal of pharmacology
researchProduct

Depression, emotional blunting, and akinesia in schizophrenia

2002

Depression, negative symptoms, and extrapyramidal signs (EPS) frequently occur together in schizophrenia. Their overlap is due partly to the lack of specificity of assessment instruments. However, to disentangle the three syndromes is clinically important as treatment of schizophrenia requires a differentiated approach. This study investigated the overlap between depression, emotional blunting as a core part of the negative syndrome, and akinesia as manifestation of EPS, using the Calgary Depression Rating Scale (CDSS), the Rating Scale for Emotional Blunting (SEB), and the akinesia score of the Simpson-Angus Scale (SAS) as the most specific assessment instruments presently available. We in…

medicine.medical_specialtyExtrapyramidal signsbusiness.industryHealth PolicyEconomics Econometrics and Finance (miscellaneous)Emotional bluntingAnhedoniamedicine.diseaseCorrelationExtrapyramidal symptomsRating scaleSchizophreniamedicinemedicine.symptombusinessPsychiatryDepression (differential diagnoses)The European Journal of Health Economics
researchProduct

Cardiovascular disease in primary sjögren’s syndrome

2018

Background A close relationship between rheumatic diseases and cardiovascular disease (CVD) has been reported, accounting for the higher mortality and morbidity observed in these patients. In the last years, it has been clearly reported that patients affected by primary Sjogren's syndrome (pSS) experienced an increased risk of CVD. Objective This review aimed at investigating CVD, traditional cardiovascular (CV) risk factors and possible targeted therapeutic strategies in pSS patients. Method Available literature concerning CV risk factors in pSS patients has been selected and discussed. Conclusion Disease-related characteristics and traditional CV risk factors contribute to observed athero…

medicine.medical_specialtyFuture studiesEndothelial damageDiseaseType 2 diabetesComorbidity030204 cardiovascular system & hematologySjögren syndrome03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineMedicineHumans030212 general & internal medicinePharmacologybusiness.industryRisk FactorGeneral Medicinemedicine.diseaseAtherosclerosisCardiovascular diseaseCardiovascular riskComorbiditySjögren syndromestomatognathic diseasesSettore MED/16 - ReumatologiaAtherosclerosis; Cardiovascular disease; Cardiovascular risk; Comorbidity; Endothelial damage; Sjögren syndrome; PharmacologyIncreased riskSjogren's SyndromeClose relationshipCardiovascular DiseasesAtherosclerosiSjogren sbusinessHuman
researchProduct

Capacidad de perdonar en pacientes en tratamiento psiquiátrico y psicológico ambulatorio

2008

Data gathered administering SCL-90-R (Spanish version) and a scale developed to assess Capacity to Forgive (CAPER) are presented. The study was carried out on a sample of 107 outpatients from Buenos Aires city and its suburban area (64 % women, 36 % men; average age: 36 years old) from a private Mental Health Center. A significant statistical negative correlation (Pearson r) was found between forgiveness and presence of psychopathological symptoms.

medicine.medical_specialtyGeneral Chemical EngineeringmedicineSuburban areaSpanish versionNegative correlationPsychiatryPsychologySocial psychologyPsicodebate
researchProduct

Interrater reliability between scorers from eight European sleep laboratories in subjects with different sleep disorders

2004

Interrater variability of sleep stage scorings is a well-known phenomenon. The SIESTA project offered the opportunity to analyse interrater reliability (IRR) between experienced scorers from eight European sleep laboratories within a large sample of patients with different (sleep) disorders: depression, general anxiety disorder with and without non-organic insomnia, Parkinson's disease, period limb movements in sleep and sleep apnoea. The results were based on 196 recordings from 98 patients (73 males: 52.3 +/- 12.1 years and 25 females: 49.5 +/- 11.9 years) for which two independent expert scorings from two different laboratories were available. Cohen's kappa was used to evaluate the IRR o…

medicine.medical_specialtyGeneralized anxiety disorderIntraclass correlationCognitive NeuroscienceGeneral MedicineAudiologymedicine.diseaseSleep in non-human animalsBehavioral NeuroscienceSiestaInter-rater reliabilitymedicinePhysical therapyInsomniamedicine.symptomPsychologyAnxiety disorderKappaJournal of Sleep Research
researchProduct